Actions of estrogenic endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate carcinogenesis

Open Biotechnology Journal

Volumn 10, Issue Suppl-1, M7, 2016, Pages 76-97

  Hu, Dan Ping ^a   Hu, Wen Yang ^a   Xie, Lishi ^a   Li, Ye ^a   Birch, Lynn ^a   Prins, Gail S ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Endocrine disrupting chemicals; Estrogen; Prostate carcinogenesis; Prostate stem progenitor cells; Stem cell division

Indexed keywords

CELL PROLIFERATION; CELL SIGNALING; CHEMICALS; CYTOLOGY; DISEASES; ENDOCRINE DISRUPTERS; ENDOCRINOLOGY; PATHOLOGY; UROLOGY;

CARCINOGENIC POTENTIAL; DEVELOPMENTAL STAGE; ENDOCRINE DISRUPTING CHEMICALS; ESTROGEN; ESTROGENIC ACTIVITIES; HORMONAL SIGNALING; PROSTATE CARCINOGENESIS; THERAPEUTIC TARGETS;

STEM CELLS;

4,4' ISOPROPYLIDENEDIPHENOL; ENDOCRINE DISRUPTOR; ESTROGEN; ESTROGEN RECEPTOR;

ARTICLE; BINDING AFFINITY; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CELL TRANSFORMATION; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; ESTROGEN SYNTHESIS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SILENCING; HORMONAL CARCINOGENESIS; HUMAN; IMMUNOHISTOCHEMISTRY; NUCLEAR REPROGRAMMING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROSTATE HYPERTROPHY; STEM CELL; TUMOR PROMOTION;

EID: 84971654954     PISSN: None     EISSN: 18740707     Source Type: Journal    
DOI: 10.2174/1874070701610010076     Document Type: Article

References (197)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics 2013. CA Cancer J Clin 2013; 63: 11-30. [http://dx.doi.org/10.3322/caac.21166]
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-907. [http://dx.doi.org/10.1158/1055-9965.EPI-10-0437]
3. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008; 100: 1672-94. [http://dx.doi.org/10.1093/jnci/djn389]
4. Huggins C, Hodges CF. Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastic carcinoma of the prostate. Cancer Res 1941; 1: 293-7.
5. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42. [http://dx.doi.org/10.1056/NEJM199810083391504]
6. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995-2005. [http://dx.doi.org/10.1056/NEJMoa1014618]
7. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375(9724): 1437-46. [http://dx.doi.org/10.1016/S0140-6736(10)60172-9]
8. Prins GS, Birch L, Tang WY, Ho SM. Developmental estrogen exposures predispose to prostate carcinogenesis with aging. Reprod Toxicol 2007; 23: 374-82. [http://dx.doi.org/10.1016/j.reprotox.2006.10.001]
9. Ellem SJ, Risbridger GP. Treating prostate cancer: A rationale for targeting local oestrogens. Natl Rev 2007; 7: 621-7. [http://dx.doi.org/10.1038/nrc2174]
10. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008; 73: 233-44. [http://dx.doi.org/10.1016/j.steroids.2007.10.013]
11. Hu WY, Shi GB, Lam HM, et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stemprogenitor cells. Endocrinology 2011; 152: 2150-63. [http://dx.doi.org/10.1210/en.2010-1377]
12. Reuben SH, LaSalle DL, Jr Kripke ML. Annual Report: Reducing Environmental Cancer Risk: What we can do now The President's Cancer Panel. National Institutes of Health; Bethesda, MD. 2010; pp. 1-147.
13. Birnbaum LS, Fenton SE. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 2003; 111: 389-94. [http://dx.doi.org/10.1289/ehp.5686]
14. Birnbaum LS. State of the science of endocrine disruptors. Environ Health Perspect 2013; 121: A107. [http://dx.doi.org/10.1289/ehp.1306695]
15. Foran CM, Peterson BN, Benson WH. Transgenerational and developmental exposure of Japanese medaka (Oryzias latipes) to ethinylestradiol results in endocrine and reproductive differences in the response to ethinylestradiol as adults. Toxicol Sci 2002; 68: 389-402. [http://dx.doi.org/10.1093/toxsci/68.2.389]
16. Heindel JJ. The fetal basis of adult disease: Role of environmental exposures-introduction. Birth Defects Res A Clin Mol Teratol 2005; 73: 131-2. [http://dx.doi.org/10.1002/bdra.20119]
17. De Coster S, van Larebeke N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health 2012. 2012: 713696
18. Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol 2011; 127: 204-15. [http://dx.doi.org/10.1016/j.jsbmb.2011.08.007]
19. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004; 101: 2371-490. [http://dx.doi.org/10.1002/cncr.20408]
20. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432: 324-31. [http://dx.doi.org/10.1038/nature03100]
21. Presnell SC, Petersen B, Heidaran M. Stem cells in adult tissues. Semin Cell Dev Biol 2002; 13: 369-76. [http://dx.doi.org/10.1016/S1084952102000939]
22. Miki J, Rhim J. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 2008; 11: 32-9. [http://dx.doi.org/10.1038/sj.pcan.4501018]
23. Kasper S. Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol Oncol 2009; 27: 301-3. [http://dx.doi.org/10.1016/j.urolonc.2008.12.012]
24. Kasper S. Stem cells: The root of prostate cancer? J Cell Physiol 2008; 216: 332-6. [http://dx.doi.org/10.1002/jcp.21489]
25. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008; 4: 193-201. [http://dx.doi.org/10.1007/s12015-008-9033-1]
26. Smith S, Neaves W, Teitelbaum S. Adult versus embryonic stem cells. Treat Sci 2007; 316: 1422-3.
27. Prins GS, Hu WY. Stem cells and prostate cancer. In: Cramer SD, Ed. Springer LLC. USA: VII 2013; pp. 1-20.
28. Prins GS, Hu WY, Shi GB, et al. Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology 2014; 155: 805-17. [http://dx.doi.org/10.1210/en.2013-1955]
29. Hu WY, Shi GB, Hu DP, Nelles JL, Prins GS. Actions of endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endoer 2012; 354: 63-73. [http://dx.doi.org/10.1016/j.mce.2011.08.032]
30. Prins GS, Ye SH, Birch L, Ho SM, Kannan K. Serum bisphenol a pharmacokinetics and prostatic responses following oral and subcutaneous exposures in neonatal sprague-dawley rats. Reprod Toxicol 2011; 31: 1-9. [http://dx.doi.org/10.1016/j.reprotox.2010.09.009]
31. Prins GS, Ho SM. Early life estrogens and prostate cancer in an animal model. J Dev Orig Health Dis 2010; 1: 365-70. [http://dx.doi.org/10.1017/S2040174410000577]
32. Prins GS, Tang WY, Belmonte J, Ho SM. Perinatal exposure to oestradiol and bisphenol a alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol 2008; 102: 134-8. [http://dx.doi.org/10.1111/j.1742-7843.2007.00166.x]
33. Prins GS. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008; 16: 649-53. [http://dx.doi.org/10.1677/ERC-08-0043]
34. Prins GS, Birch L, Ye SH, Ray V. Estrogen exposure leads to prostate lobe-specific dysplasia and adenomas in the aging rat. Minneapolis, MN: American Society of Andrology 1996.
35. Prins GS, Birch L. Neonatal estrogen up-regulates estrogen receptor in prostatic smooth muscle cells and increases extracellular TGFb1. Program of the 76th Annual Meeting of the Endocrine Society. Anaheim, CA. 1994.
36. Prins GS, Woodham C, Lepinske M, Birch L. Effects of neonatal estrogen exposure on prostatic secretory genes and their correlation with androgen receptor expression in the separate prostate lobes of the adult rat. Endocrinology 1993; 132: 2387-98.
37. Prins GS. Neonatal estrogen exposure induces lobe-specific alterations in adult rat prostate androgen receptor expression. Endocrinology 1992; 130: 3703-14. [http://dx.doi.org/10.1210/en.130.6.3703]
38. Harkonen PL, Makela S. Role of estrogens in the development of prostate cancer. Steroid Biochem Mol Biol 2004; 92: 297-305. [http://dx.doi.org/10.1016/j.jsbmb.2004.10.016]
39. Huang L, Pu Y, Alam S, Birch L, Prins GS. Estrogenic regulation of signaling pathways and homeobox genes during rat prostate development. J Androl 2004; 25: 330-7. [http://dx.doi.org/10.1002/j.1939-4640.2004.tb02796.x]
40. Ellem SJ, Risbridger GP. The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 2009; 1155: 174-86. [http://dx.doi.org/10.1111/j.1749-6632.2009.04360.x]
41. Bosland MC. Chemical and hormonal induction of prostate cancer in animal models. Urol Oncol 1996; 2: 103-10. [http://dx.doi.org/10.1016/S1078-1439(97)82840-2]
42. Ricke W, Ishii K, Ricke EA, et al. Steroid hormones stimulate human prostate cancer progression and metastasis. Int J Cancer 2006; 118: 2123-31. [http://dx.doi.org/10.1002/ijc.21614]
43. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 2008; 22: 1512-20. [http://dx.doi.org/10.1096/fj.07-9526com]
44. Yu S, Zhang Y, Yuen MT, Zou C, Danielpour D, Chan FL. 17-Beta-estradiol induces neoplastic transformation in prostatic epithelial cells. Cancer Lett 2011; 304: 8-20. [http://dx.doi.org/10.1016/j.canlet.2011.01.003]
45. Modugno F, Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001; 7: 3092-6.
46. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP. Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 2004; 89: 2431-41. [http://dx.doi.org/10.1210/jc.2003-030933]
47. Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 2010; 10: 244-51. [http://dx.doi.org/10.1186/1471-2407-10-244]
48. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-54. [http://dx.doi.org/10.1158/0008-5472.CAN-08-0249]
49. Yu L, Wang CY, Shi J, et al. Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. Endocrinology 2011; 152: 773-81. [http://dx.doi.org/10.1210/en.2010-1239]
50. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100: 815-25. [http://dx.doi.org/10.1093/jnci/djn150]
51. Miro AM, Sastre-Serra J, Pons DG, Valle A, Roca P, Oliver J. 17beta-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol 2011; 123: 133-9. [http://dx.doi.org/10.1016/j.jsbmb.2010.12.004]
52. Nelson WG, Demarzo AM, Yegnasubramanian S. The diet as a cause of human prostate cancer. Cancer Treat Res 2014; 159: 51-68. [http://dx.doi.org/10.1007/978-3-642-38007-5_4]
53. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85. [http://dx.doi.org/10.1056/NEJM200007133430201]
54. Marks LS, Kojima M, Demarzo A, et al. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology 2004; 64: 765-71. [http://dx.doi.org/10.1016/j.urology.2004.05.047]
55. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30: 293-342. [http://dx.doi.org/10.1210/er.2009-0002]
56. Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol 2014; 140: 116-32. [http://dx.doi.org/10.1016/j.jsbmb.2013.12.010]
57. Cao Y, Calafat AM, Doerge DR, et al. Isoflavones in urine, saliva, and blood of infants: data from a pilot study on the estrogenic activity of soy formula. J Expo Sci Environ Epidemiol 2009; 19: 223-34. [http://dx.doi.org/10.1038/jes.2008.44]
58. Morrison H, Savitz D, Semenciw R, et al. Farming and prostate cancer mortality. Am J Epidemiol 1993; 137: 270-80.
59. Meyer TE, Coker AL, Sanderson M, Symanski E. A case-control study of farming and prostate cancer in African-American and Caucasian men. Occup Environ Med 2007; 64: 155-60. [http://dx.doi.org/10.1136/oem.2006.027383]
60. Alavanja MC, Samanic C, Dosemeci M, et al. Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort. Am J Epidemiol 2003; 157: 800-14. [http://dx.doi.org/10.1093/aje/kwg040]
61. Van Maele-Fabry G, Libotte V, Willems J, Lison D. Review and meta-analysis of risk estimates for prostate cancer in pesticide manufacturing workers. Cancer Causes Control 2006; 17: 353-73. [http://dx.doi.org/10.1007/s10552-005-0443-y]
62. Kuroda M, Oikawa K, Ohbayashi T, et al. A dioxin sensitive gene, mammalian WAPL, is implicated in spermatogenesis. FEBS Lett 2005; 579: 167-72. [http://dx.doi.org/10.1016/j.febslet.2004.11.070]
63. Benbrahim-Tallaa L, Liu J, Webber MM, Waalkes MP. Estrogen signaling and disruption of androgen metabolism in acquired androgenindependence during cadmium carcinogenesis in human prostate epithelial cells. Prostate 2007; 67: 135-45. [http://dx.doi.org/10.1002/pros.20479]
64. Huff J, Lunn RM, Waalkes MP, Tomatis L, Infante PF. Cadmium-induced cancers in animals and in humans. Int J Occup Environ Health 2007; 13: 202-12. [http://dx.doi.org/10.1179/oeh.2007.13.2.202]
65. Prince MM, Ruder AM, Hein MJ, et al. Mortality and exposure response among 14,458 electrical capacitor manufacturing workers exposed to polychlorinated biphenyls (PCBs). Environ Health Perspect 2006; 114: 1508-14. [http://dx.doi.org/10.1289/ehp.9175]
66. Ritchie JM, Vial SL, Fuortes LJ, Guo H, Reedy VE, Smith EM. Organochlorines and risk of prostate cancer. J Occup Environ Med 2003; 45: 692-702. [http://dx.doi.org/10.1097/01.jom.0000071510.96740.0b]
67. Charles LE, Loomis D, Shy CM, et al. Electromagnetic fields, polychlorinated biphenyls, and prostate cancer mortality in electric utility workers. Am J Epidemiol 2003; 157: 683-91. [http://dx.doi.org/10.1093/aje/kwg044]
68. Mahajan R, Blair A, Lynch CF, et al. Fonofos exposure and cancer incidence in the agricultural health study. Environ Health Perspect 2006; 114: 1838-42. [http://dx.doi.org/10.1289/ehp.8911]
69. Usmani KA, Rose RL, Hodgson E. Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. Drug Metab Dispos 2003; 31: 384-91. [http://dx.doi.org/10.1124/dmd.31.4.384]
70. Usmani KA, Cho TM, Rose RL, Hodgson E. Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos 2006; 34: 1606-14. [http://dx.doi.org/10.1124/dmd.106.010439]
71. Kester MH, Bulduk S, van Toor H, et al. Potent inhibition of estrogen sulfotransferase by hydroxylated metabolites of polyhalogenated aromatic hydrocarbons reveals alternative mechanism for estrogenic activity of endocrine disrupters. J Clin Endo Metab 2002; 87: 1142-50. [http://dx.doi.org/10.1210/jcem.87.3.8311]
72. Kester MH, Bulduk S, Tibboel D, et al. Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology 2000; 141: 1897-900. [http://dx.doi.org/10.1210/endo.141.5.7530]
73. Alonso-Magdalena P, Ropero AB, Soriano S, et al. Bisphenol-A acts as a potent estrogen via non-classical estrogen triggered pathways. Mol Cell Endocrinol 2012; 355(2): 201-7. [http://dx.doi.org/10.1016/j.mce.2011.12.012]
74. Zhou L, Le Roux G, Ducrot C, et al. Repression of class I transcription by cadmium is mediated by the protein phosphatase 2A. Nucleic Acids Res 2013; 41(12): 6087-97. [http://dx.doi.org/10.1093/nar/gkt335]
75. Soto AM, Sonnenschein C, Chung KL, Fernandez MF, Olea N, Serrano FO. The E-SCREEN assay as a tool to identify estrogens: an update on estrogenic environmental pollutants. Environ Health Perspect 1995; 103(Suppl. 7): 113-22. [http://dx.doi.org/10.1289/ehp.95103s7113]
76. Benbrahim-Tallaa L, Waalkes MP. Inorganic arsenic and human prostate cancer. Environ Health Perspect 2008; 116: 158-64. [http://dx.doi.org/10.1289/ehp.10423]
77. Matthews J, Gustafsson JA. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal 2006; 4: e016.
78. Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol 2011; 24: 6-19. [http://dx.doi.org/10.1021/tx100231n]
79. Dodds EC, Lawson W. Synthetic oestrogenic agents without phenanthrene nucleus. Nature 1936; 137: 996-7. [http://dx.doi.org/10.1038/137996a0]
80. Stahlhut RW, Welshons WV, Swan SH. Bisphenol A data in NHANES suggest longer than expected half-life, substantial nonfood exposure, or both. Environ Health Perspect 2009; 117: 784-9. [http://dx.doi.org/10.1289/ehp.0800376]
81. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect 2008; 116: 39-44. [http://dx.doi.org/10.1289/ehp.10753]
82. Kuroda N, Kinoshita Y, Sun Y, et al. Measurement of bisphenol A levels in human blood serum and ascitic fluid by HPLC using a fluorescent labeling reagent. J Pharm Biol Anal 2003; 30: 1743-9. [http://dx.doi.org/10.1016/S0731-7085(02)00516-2]
83. Lee YJ, Ryu HY, Kim HK, et al. Maternal and fetal exposure to bisphenol A in Korea. Reprod Toxicol 2008; 25: 413-9. [http://dx.doi.org/10.1016/j.reprotox.2008.05.058]
84. Calafat AM, Weuve J, Ye X, et al. Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants. Environ Health Perspect 2009; 117: 639-44. [http://dx.doi.org/10.1289/ehp.0800265]
85. Eddington AN, Ritter L. Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic model. Environ Health Perspect 2009; 117: 645-52. [http://dx.doi.org/10.1289/ehp.0800073]
86. Ikezuki Y, Tsutsumi O, Takai Y, Kamiei Y, Taketani Y. Determination of bisphenol A concentrations in human biological fluids reveals significant early prenatal exposure. Hum Reprod 2002; 17: 2839-14. [http://dx.doi.org/10.1093/humrep/17.11.2839]
87. Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor b. Endocrinology 1998; 139: 4252-63.
88. Lemmen JG, Arends RJ, van der Saag PT, van der Burg B. In vivo imaging of activated estrogen receptors in utero by estrogens and bisphenol A. Environ Health Perspect 2004; 112: 1544-9. [http://dx.doi.org/10.1289/ehp.7155]
89. Song KH, Lee K, Choi HS. Endocrine disruptor bisphenol A induces orphan nuclear receptor Nur77 gene expression and steroidogenesis in mouse testicular Leydig cells. Endocrinology 2002; 143: 2208-15. [http://dx.doi.org/10.1210/endo.143.6.8847]
90. Walsh DE, Dockery P, Doolan CM. Estrogen receptor independent rapid non-genomic effects of environmental estrogens on [Ca2+]i in human breast cancer cells. Mol Cell Endocrinol 2005; 230: 23-30. [http://dx.doi.org/10.1016/j.mce.2004.11.006]
91. Kurosawa T, Hiroi H, Tsutsumi O, et al. The activity of bisphenol A depends on both the estrogen receptor subtype and the cell type. Endocr J 2002; 49: 465-71. [http://dx.doi.org/10.1507/endocrj.49.465]
92. Fan W, Yanase T, Morinaga H, et al. Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans. Environ Health Perspect 2007; 115: 720-7. [http://dx.doi.org/10.1289/ehp.9758]
93. Delfosse V, Grimaldi M, Pons JL, et al. Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad Sci USA 2012; 109: 14930-5. [http://dx.doi.org/10.1073/pnas.1203574109]
94. Maffini MV, Rubin BS, Sonnenschein C, Soto AM. Endocrine disruptors and reproductive health: the case of bisphenol-A. Mol Cell Endocrinol 2006; 254-255: 179-86. [http://dx.doi.org/10.1016/j.mce.2006.04.033]
95. Keri R, Ho SM, Hunt PA, Knudsen KE, Soto AM, Prins GS. An Evaluation of evidence for the carcinogenic activity of bisphenol a: report of NIEHS expert panel on BPA. Reprod Toxicol 2007; 24: 240-52. [http://dx.doi.org/10.1016/j.reprotox.2007.06.008]
96. Ho SM, Tang WY, Belmonte J, Prins GS. Developmental exposure to estradiol and bisphenol A (BPA) increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant (PDE4D4) in the rat prostate. Cancer Res 2006; 66: 5624-32. [http://dx.doi.org/10.1158/0008-5472.CAN-06-0516]
97. Tarapore P, Ying J, Ouyang B, Burke B, Bracken B, Ho SM. Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro. PLoS One 2014; 9: e90332. [http://dx.doi.org/10.1371/journal.pone.0090332]
98. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res 2005; 65: 54-65.
99. Wetherill YB, Hess-Wilson JK, Comstock CE, et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther 2006; 5: 3181-90. [http://dx.doi.org/10.1158/1535-7163.MCT-06-0272]
100. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26: 833-76. [http://dx.doi.org/10.1210/er.2004-0013]
101. Ng JC, Wang J, Shraim A. A global health problem caused by arsenic from natural sources. Chemosphere 2003; 52: 1353-9. [http://dx.doi.org/10.1016/S0045-6535(03)00470-3]
102. Hughes MF. Arsenic methylation, oxidative stress and cancer-is there a link? J Natl Cancer Inst 2009; 101: 1660-1. [http://dx.doi.org/10.1093/jnci/djp437]
103. Drobna Z, Naranmandura H, Kubachka KM, et al. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem Res Toxicol 2009; 22: 1713-20. [http://dx.doi.org/10.1021/tx900179r]
104. Gruber JJ, Zatechka DS, Sabin LR, et al. Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell 2009; 138: 328-39. [http://dx.doi.org/10.1016/j.cell.2009.04.046]
105. Waalkes MP, Liu J, Diwan BA. Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol 2007; 222: 271-80. [http://dx.doi.org/10.1016/j.taap.2006.12.034]
106. Tokar EJ, Qu W, Waalkes MP. Arsenic, Stem cells and the developmental basis of adult cancer. Toxicol Sci 2011; 120: S192-203. [http://dx.doi.org/10.1093/toxsci/kfq342]
107. Waalkes MP, Liu J, Diwan BA. Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol 2007; 222: 271-80. [http://dx.doi.org/10.1016/j.taap.2006.12.034]
108. Knobeloch LM, Zierold KM, Anderson HA. Association of arsenic-contaminated drinking-water with prevalence of skin cancer in Wisconsin's Fox River Valley. J Health Popul Nutr 2006; 24: 206-13.
109. Chen CJ, Kuo T, Wu M. Aresenic and cancers. Lancet 1988; 1: 414-5. [http://dx.doi.org/10.1016/S0140-6736(88)91207-X]
110. Chen CJ, Wang CJ. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 1990; 50: 5470-4.
111. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon R. Drinking water aresenic in Utah: A cohort mortality study. Environ Health Perspect 1999; 107: 359-65. [http://dx.doi.org/10.1289/ehp.99107359]
112. Davey JC, Bodwell JE, Gosse JA, Hamilton J. Arsenic as an endocrine disruptor: effects of arsenic on estrogen receptor-mediated gene expression in vivo and in cell culture. Toxicol Sci 2007; 98: 75-86. [http://dx.doi.org/10.1093/toxsci/kfm013]
113. Davey JC, Nomikos AP, Wungjiranirun M, et al. Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis. Environ Health Perspect 2008; 116: 165-72. [http://dx.doi.org/10.1289/ehp.10131]
114. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. Environ Health Natl Camcer Inst 2002; 94: 1888-91. [http://dx.doi.org/10.1093/jnci/94.24.1888]
115. Benbrahim-Tallaa L, Waterland RA, Styblo M, Achanzar WE, Webber MM, Waalkes MP. Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol 2005; 206: 1134-9. [http://dx.doi.org/10.1016/j.taap.2004.11.017]
116. Benbrahim-Tallaa L, Webber MM, Waalkes MP. Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect 2007; 115: 2.
117. Tokar EJ, Qu W, Liu J, et al. Arsenic-specific stem cell selection during malignant transformation. Environ Health Natl Camcer Inst 2010; 102: 638-49. [http://dx.doi.org/10.1093/jnci/djq093]
118. Tokar EJ, Diwan BA, Waalkes MP. Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect 2010; 118: 108-15.
119. Tokar EJ, Benbrahim-Tallaa L, Ward JM, Lunn R, Sams RL, Waalkes MP. Cancer in experimental animals exposed to arsenic and arsenic compounds. Crit Rev Toxicol 2010; 40: 912-27. [http://dx.doi.org/10.3109/10408444.2010.506641]
120. Xu Y, Tokar EJ, Sun Y, Waalkes MP. Arsenic-transformed malignant prostate epithelia can convert noncontiguous normal stem cells into an oncogenic phenotype. Environ Health Perspect 2012; 120: 865-71. [http://dx.doi.org/10.1289/ehp.1204987]
121. Singh KP, Kumari R, Treas J, DuMond JW. Chronic exposure to arsenic causes increased cell survival, DNA damage, and increased expression of mitochondrial transcription factor A (mtTFA) in human prostate epithelial cells. Chem Res Toxicol 2011; 24: 340-9. [http://dx.doi.org/10.1021/tx1003112]
122. Rossman TG. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 2003; 533: 37-65. [http://dx.doi.org/10.1016/j.mrfmmm.2003.07.009]
123. Kojima C, Ramirez DC, Tokar EJ, et al. Requirement of arsenic biomethylation for oxidative DNA damage. Environ Health Natl Camcer Inst 2009; 101: 1670-81. [http://dx.doi.org/10.1093/jnci/djp414]
124. Treas JN, Tyagi T, Singh KP. Effects of chronic exposure to arsenic and estrogen on epigenetic regulatory genes expression and epigenetic code in human prostate epithelial cells. PLoS One 2012; 7: e43880. [http://dx.doi.org/10.1371/journal.pone.0043880]
125. Treas J, Tyagi T, Singh KP. Chronic exposure to arsenic, estrogen, and their combination causes increased growth and transformation in human prostate epithelial cells potentially by hypermethylation-mediated silencing of MLH1. Prostate 2013; 73: 1660-72.
126. Ngalame NN, Tokar EJ, Person RJ, Xu Y, Waalkes MP. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol Sci 2014; 138: 268-77. [http://dx.doi.org/10.1093/toxsci/kfu002]
127. Cunha G, Fujii H, Neubauer B, Shannon J, Sawyer L, Reese B. Epithelial-mesenchymal interactions in prostatic development. I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983; 96: 1662-70. [http://dx.doi.org/10.1083/jcb.96.6.1662]
128. Cunha GR. The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 1973; 175: 87-96. [http://dx.doi.org/10.1002/ar.1091750108]
129. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-63. [http://dx.doi.org/10.1210/edrv-8-3-338]
130. Long RM, Morrissey C, Fitzpatrick JM, Watson RW. Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) 2005; 108: 1-11. [http://dx.doi.org/10.1042/CS20040241]
131. Prins GS. Reproductive Issues and the Aging Male. In: Haseltine F, Paulsen C, Wang C, Eds. Embryonic, Inc. New York 1993; pp. 101-12.
132. Prins GS, Putz O. Molecular signaling pathways that regulate prostate gland development. Differentiation 2008; 76: 641-59. [http://dx.doi.org/10.1111/j.1432-0436.2008.00277.x]
133. Chung LW, Cunha GR. Stromal-epithelial interactions: II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 1983; 4: 503-11. [http://dx.doi.org/10.1002/pros.2990040509]
134. Isaacs JT, Barrack ER, Isaacs WB, Coffey DS. The Prostatic Cell: Structure and function In: Alan R, Ed. New York: Liss, Inc 1981; pp. 1-24. Part A. [PMID: 7200232]
135. Wang Y, Hayward SW, Cao M, Thayer K, Cunha GR. Cell differentiation lineage in the prostate. Differentiation 2001; 68: 270-9. [http://dx.doi.org/10.1046/j.1432-0436.2001.680414.x]
136. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999; 13: 966-77. [http://dx.doi.org/10.1101/gad.13.8.966]
137. Hayward S, Cunha G, Dahiya R. Normal development and carcinogenesis of the prostate; A unifying hypothesis. Ann N Y Acad Sci 1996; 784: 50-62. [http://dx.doi.org/10.1111/j.1749-6632.1996.tb16227.x]
138. Wang H, McKnight NC, Zhang T, Lu ML, Balk SP, Yuan X. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells. Cancer Res 2007; 67: 528-36. [http://dx.doi.org/10.1158/0008-5472.CAN-06-1672]
139. Rumpold H, Heinrich E, Untergasser G, et al. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 2002; 53: 101-8. [http://dx.doi.org/10.1002/pros.10129]
140. van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 2002; 51: 98-107. [http://dx.doi.org/10.1002/pros.10073]
141. Garraway IP, Sun W, Tran CP, et al. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 2010; 70: 491-501.
142. Garraway LA, Lin D, Signoretti S, et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003; 55: 206-18. [http://dx.doi.org/10.1002/pros.10244]
143. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 2008; 105: 20882-7. [http://dx.doi.org/10.1073/pnas.0811411106]
144. Isaacs JT. Prostate stem cells and benign prostatic hyperplasia. Prostate 2008; 68: 1025-34. [http://dx.doi.org/10.1002/pros.20763]
145. Kasper S. Characterizing the prostate stem cell. J Urol 2007; 178: 375. [http://dx.doi.org/10.1016/j.juro.2007.05.031]
146. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 2010; 107: 2610-5. [http://dx.doi.org/10.1073/pnas.0913873107]
147. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single cell. Nature 2008; 456: 804-8. [http://dx.doi.org/10.1038/nature07427]
148. Liu J, Pascal LE, Isharwal S, et al. Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate. Mol Endocrinol 2011; 25: 1849-57. [http://dx.doi.org/10.1210/me.2011-1081]
149. Xin L, Lukacs RU, Lawson DA, Cheng D, Witte ON. Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells 2007; 25: 2760-9. [http://dx.doi.org/10.1634/stemcells.2007-0355]
150. Cunha GR. Epithelial-stromal interactions in development of the urogenital tract. Int Rev Cytol 1976; 47: 137-94. [http://dx.doi.org/10.1016/S0074-7696(08)60088-1]
151. Cunha GR. Progress in cancer research and therapy. In: Bresciani F, Ed. New York: Raven Press 1984; Vol. 31: pp. 121-8.
152. Tsujimura A, Koikawa Y, Salm S, et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. JCB 2002; 157: 1257-65. [http://dx.doi.org/10.1083/jcb.200202067]
153. Goto K, Salm SN, Xiong X, et al. Proximal prostatic stem cells are programmed to regenerate a proximal-distal ductal axis. Stem Cells 2006; 24: 1859-68. [http://dx.doi.org/10.1634/stemcells.2005-0585]
154. Hudson DL. Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 2004; 7: 188-94. [http://dx.doi.org/10.1038/sj.pcan.4500745]
155. De Marzo A, Nelson W, Meeker A, Coffey D. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160: 2381-92. [http://dx.doi.org/10.1016/S0022-5347(01)62196-7]
156. Burger PE, Xiong X, Coetzee S, et al. Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. Proc Natl Acad Sci USA 2005; 102: 180-5. [http://dx.doi.org/10.1073/pnas.0502761102]
157. Morrison SJ, Kimble J. Assymetric and symetric stem cell divisions in development and cancer. Nature 2006; 441: 1068-74. [http://dx.doi.org/10.1038/nature04956]
158. Scaffidi P, Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011; 19: 1051-6. [http://dx.doi.org/10.1038/ncb2308]
159. Tomasetti C, Levy D. Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci USA 2010; 107: 16766-71. [http://dx.doi.org/10.1073/pnas.1007726107]
160. Peehl DM. Prostate Cancer Methods and Protocols. In: Russell PJ, Kingsley EA, Eds. Totowa, NJ: Humana Press 2003; pp. 41-57.
161. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc 2010; 5: 702-13. [http://dx.doi.org/10.1038/nprot.2010.11]
162. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005; 102: 6942-7. [http://dx.doi.org/10.1073/pnas.0502320102]
163. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001; 114: 3865-72.
164. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008; 68: 9703-11. [http://dx.doi.org/10.1158/0008-5472.CAN-08-3084]
165. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2003; 117: 3539-45. [http://dx.doi.org/10.1242/jcs.01222]
166. Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci 2010; 86: 631-7. [http://dx.doi.org/10.1016/j.lfs.2010.02.012]
167. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-34. [http://dx.doi.org/10.1038/nm0901-1028]
168. Brown MD, Gilmore PE, Hart CA, et al. Characterization of benign and malignant prostate epithelial Hoeschst 33342 side populations. Prostate 2007; 67: 1384-96. [http://dx.doi.org/10.1002/pros.20620]
169. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc 2010; 5: 702-13. [http://dx.doi.org/10.1038/nprot.2010.11]
170. Lang SH, Stark M, Collins A, Paul AP, Stower MJ, Maitland NJ. Experimental prostate morphogenesis in response to stroma and three dimensional matrigel culture. Cell Growth Differ 2001; 12: 631-40.
171. Hudson DL. Epithelial cell culture protocols. In: Wise C, Ed. Totowa, New Jersey: Humana Press 2002; pp. 77-84.
172. Mollard R, Shyselinck N, Wendling O, Chamson P, Mark M. Stage-dependent responses of the developing lung to retinoic acid signaling. Int J Dev Biol 2000; 44: 457-62.
173. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT, van der Burg B. Tissue-and time-dependent estrogen receptor activation in estrogen reporter mice. J Mol Endocrinol 2004; 32: 689-701. [http://dx.doi.org/10.1677/jme.0.0320689]
174. Barba M, Yang L, Schunemann HJ, et al. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. J Exp Clin Cancer Res 2009; 28: 135. [http://dx.doi.org/10.1186/1756-9966-28-135]
175. Weiner JM, Marmorston J, Stern E, Hopkins CE. Urinary hormone metabolites in cancer and benign hyperplasia of the prostate: a multivariate statistical analysis. Ann N Y Acad Sci 1966; 125: 974-83. [http://dx.doi.org/10.1111/j.1749-6632.1966.tb45449.x]
176. Steiner MS, Pound CR. Phase IIA clinical trial to test the efficacy and safety of Toremifene in men with high-grade prostatic intraepithelial neoplasia. Clin Prostate Cancer 2003; 2: 24-31. [http://dx.doi.org/10.3816/CGC.2003.n.009]
177. Lowsley OS. The development of the human prostate gland with reference to the development of other structures at the neck of the urinary bladder. Am J Anat 1912; 13: 299-348. [http://dx.doi.org/10.1002/aja.1000130303]
178. Hayward SW, Wang Y, Cao M, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001; 61: 8135-42.
179. Henderson B, Ross R, Pike M, Casagrande J. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42: 3232-9.
180. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 1988; 57: 216-8. [http://dx.doi.org/10.1038/bjc.1988.46]
181. Fouse SD, Shen Y, Pellegrini M, et al. Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation. Cell Stem Cell 2008; 2: 160-9. [http://dx.doi.org/10.1016/j.stem.2007.12.011]
182. Blackwood JK, Williamson SC, Greaves LC, et al. In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J Pathol 2011; 225: 181-8. [http://dx.doi.org/10.1002/path.2965]
183. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-71. [http://dx.doi.org/10.1126/science.1189992]
184. Stoyanova T, Cooper AR, Drake JM, et al. Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci USA 2013; 110: 20111-6. [http://dx.doi.org/10.1073/pnas.1320565110]
185. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67: 4708-15. [http://dx.doi.org/10.1158/0008-5472.CAN-06-4608]
186. Smith S, Neaves W, Teitelbaum S. Adult versus embryonic stem cells: Treatments. Science 2007; 316(5830) [http://dx.doi.org/10.1126/science.316.5830.1422b]
187. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008; 26: 2862-70. [http://dx.doi.org/10.1200/JCO.2007.15.1472]
188. Oldridge EE, Pellacani D, Collins AT, Maitland NJ. Prostate cancer stem cells: Are they androgen-responseive? Mol Cell Endocrinol 2012; 360(1-2): 14-24. [http://dx.doi.org/10.1016/j.mce.2011.07.008]
189. Cocciadiferro L, Miceli V, Kang KS, Polito LM, Trosko JE, Carruba G. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann N Y Acad Sci 2009; 1155: 257-62. [http://dx.doi.org/10.1111/j.1749-6632.2009.03696.x]
190. Liu AY, True L. Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 2002; 160: 37-43. [http://dx.doi.org/10.1016/S0002-9440(10)64346-5]
191. Cheng AS, Culhane AC, Chan MW, et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res 2008; 68: 1786-96. [http://dx.doi.org/10.1158/0008-5472.CAN-07-5547]
192. Cairns J. Mutation selection and the natural history of cancer. Nature 1975; 255: 197-200. [http://dx.doi.org/10.1038/255197a0]
193. Cairns J. Cancer and the immortal strand hypothesis. Genetics 2006; 174: 1069-72. [http://dx.doi.org/10.1534/genetics.104.66886]
194. Pu Y, Huang L, Prins GS. Neonatal estrogen exposure alters epithelial differentiation in rat prostate through down regulation of Hoxb-13. J Androl 2004; 25(81)(Suppl. S) Ch. 129. Available from: http://eurekamag.com/research/035/374/035374278.php
195. Giangreco AA, Vaishnav A, Wagner D, et al. Tumor suppressor microRNAs, miR-100 and-125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue. Cancer Prev Res (Phila) 2013; 6: 483-94. [http://dx.doi.org/10.1158/1940-6207.CAPR-12-0253]
196. Goldstein AS, Staoyanova T, Witte ON. Primitive origins of prostate cancer: In vivo evidence for prostate-regenerating cells and prostatecancer initiating cells. Mol Oncol 2010; 4: 385-96. [http://dx.doi.org/10.1016/j.molonc.2010.06.009]
197. Newbold RR, Padilla-Banks E, Jefferson WN. Adverse effects of the model environmental estrogen diethylstilbestrol are transmitted to subsequent generations. Endocrinology 2006; 147: S11-7. [http://dx.doi.org/10.1210/en.2005-1164]